Given the above concerns and lack of data in the ICU setting, we conducted a pilot case–control study in ICU patients with type 2 diabetes receiving insulin aiming to evaluate whether the potential to reduce insulin requirements using the SGLT2 inhibitor empagliflozin outweighed the risk of ketoacidosis. This evidence concerns the gene INS and type 2 diabetes mellitus.